Market Overview
The Global Pain Management Devices Market reached US$ 3.8 billion in 2024 and is expected to reach US$ 8.3 billion by 2033, growing at a CAGR of 9.2% during the forecast period 2025-2033.
Pain management devices are specialized medical tools designed to alleviate chronic and acute pain, improve patient quality of life, and reduce dependency on pharmacological treatments such as opioids. These devices employ various technologies, including electrical stimulation, heat therapy, cryotherapy, and drug delivery systems, to target pain at its source and provide relief either directly or indirectly.
Pain management devices play a crucial role in modern healthcare by providing effective solutions for conditions where traditional methods may be insufficient or carry significant risks, such as opioid addiction. They empower patients with better control over their pain and enhance the efficiency of pain management in clinical and home settings.
The global pain management devices market is experiencing significant growth, driven by factors such as the increasing prevalence of chronic pain conditions, technological advancements and a growing preference for non-invasive treatment options. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2021, an estimated 20.9% of U.S. adults (51.6 million persons) experienced chronic pain, and 6.9% (17.1 million persons) experienced high-impact chronic pain, driving the demand for effective pain management devices.
Executive Summary
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
Rising technological advancements in pain management devices
The rising technological advancements in pain management devices are significantly driving the growth of the Pain Management Devices market and are expected to drive the market over the forecast period. Technologies like Spinal Cord Stimulation and Peripheral Nerve Stimulation are becoming more advanced, providing targeted pain relief with precise control over stimulation parameters. These advancements not only improve pain relief but also enhance patient satisfaction by allowing more personalized settings.
For instance, in January 2023, Abbott cleared the U.S. Food and Drug Administration (FDA) approval for its Proclaim XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes. The Proclaim XR SCS system can provide relief to DPN patients in need of alternatives to traditional treatment approaches, such as oral medication. People who receive therapy from the Proclaim XR SCS system will also be able to use Abbott's NeuroSphere Virtual Clinic, a connected care app that allows people to communicate with a physician and receive treatment adjustments remotely.
The use of AI in pain management devices is driving personalized treatment plans. These technologies analyze patient data in real time, adjusting device parameters for optimal pain relief. For instance, in September 2024, Nevro Corp. announced the U.S. Food and Drug Administration (FDA) approval and limited market release of HFX iQ with HFX AdaptivAI, the Only AI-driven technology in spinal cord stimulation, a responsive, personalized pain management platform powering the HFX iQ spinal cord stimulation (SCS) system.
Minimally invasive and non-invasive procedures are becoming the norm due to technological advancements in imaging and guidance systems. For instance, in September 2024, Zynex Inc. announced FDA clearance of its new TensWave device. The TensWave device, by prescription only, builds on Zynex's strong legacy of innovation in pain management. It offers a user-friendly, portable design that can be easily integrated into patients' daily routines. The device aims to provide effective pain relief through TENS (Transcutaneous Electrical Nerve Stimulation) therapy, which has been clinically proven to reduce chronic and acute pain without needing medication.
High cost of pain management devices
The high cost of pain management devices is expected to hamper the growth of the market over the forecast period. The cost of advanced pain management devices such as spinal cord stimulators, neurostimulation devices, and infusion pumps can be prohibitive for many patients. These devices often require upfront payments that are beyond the reach of many individuals, especially in countries where insurance coverage for such devices is limited or nonexistent.
For instance, according to the Physician Partners of America, the price for a spinal cord stimulator ranges from $7,000-$10,000 depending on the practice. Additionally, a Boston Scientific Spinal Cord Stimulator costs around $19,000 for newer models.
The high cost of these devices especially fro deep brain stimulation devices and procedures is a significant factor that hampers market growth by limiting access and affordability for a large segment of potential patients. This financial barrier affects adoption rates, particularly in low- and middle-income regions and impacts both healthcare providers and patients.
For instance, according to the National Institute of Health, 2024, the inflation and currency-adjusted mean cost of the DBS device was USD 21,496.07 ± USD 8,944.16, the cost of surgery alone was USD 14,685.22 ± USD 8,479.66, the total cost of surgery was USD 40,942.85 ± USD 17,987.43 and the total cost of treatment until 1 year of follow-up was USD 47,632.27 ± USD 23,067.08.
Market Segment Analysis
The global pain management devices market is segmented based on product type, application, end-user and region.
Product Type:
The neurostimulation devices segment is expected to dominate the pain management devices market share
Neurostimulation devices, such as Spinal Cord Stimulation (SCS) and Deep Brain Stimulation (DBS), are highly effective in managing chronic pain by targeting specific pain pathways. This targeted approach allows for customized treatment settings that adapt to the patient’s specific pain pattern.
For instance, in January 2024, Abbott received approval from the U.S. Food and Drug Administration (FDA) to launch the Liberta RC DBS system, the world's smallest rechargeable deep brain stimulation (DBS) device with remote programming. The Liberta RC DBS system requires the fewest recharges of any FDA-approved DBS system, needing only 10 recharge sessions a year for most people.
Neurostimulation devices are used to treat a broad spectrum of chronic pain conditions, including neuropathic pain, back pain, post-surgical pain, and migraine. For instance, in February 2024, Boston Scientific Corporation cleared U.S. Food and Drug Administration (FDA) approval for an expanded indication of the WaveWriter SCS Systems for the treatment of chronic low back and leg pain in people without prior back surgery, commonly referred to as non-surgical back pain (NSBP). The versatility of neurostimulation devices contributes to their dominance in the market as they cater to multiple patient needs with different pain profiles.
Advances in neurostimulation technology, such as minimally invasive implantation techniques, have made these devices more accessible and less intimidating for patients. The devices with a wearable approach that can be adjusted via smartphone, make it user-friendly and more acceptable to patients who may otherwise be resistant to invasive surgery.
For instance, in April 2023, Neuspera Medical, a medical device company developing implantable devices for patients battling chronic illnesses, announced that it received U.S. Food and Drug Administration (FDA) clearance for the next-generation Neuspera ultra-miniaturized system. The system is comprised of a micro-implant that delivers neurostimulation therapy through a wireless platform including a wearable transmitter and iPad-based clinician programmer.
Market Geographical Analysis
North America is expected to hold a significant position in the pain management devices market share
North America especially the United States is home to several major players in the pain management devices market, including Medtronic, Stryker Corporation, Boston Scientific, Abbott and other emerging players. These companies have extensive R&D operations in the region, focusing on the development of advanced pain management solutions, resulting in innovations, which integrate advancements for personalized pain management.
For instance, in April 2024, Medtronic plc announced that the U.S. Food and Drug Administration (FDA) has approved the Inceptiv closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain. Inceptiv is the first Medtronic SCS device to offer a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts stimulation in real-time, keeping therapy in harmony with the motions of daily life.
Additionally, in July 2024, Stryker launched the MultiGen 2 Radiofrequency (RF) Generator, this technology provides physicians with the efficiency, control and reliability they need when performing RF ablation, a minimally invasive procedure that can provide lasting relief to those suffering from facet joint pain. MultiGen 2 is the next generation of radiofrequency ablation that provides physicians with control and customization to perform chronic pain management procedures with confidence.
The U.S. FDA’s rigorous but predictable approval process makes North America an ideal market for new pain management devices. Companies like Abbott and Boston Scientific frequently conduct pivotal clinical trials in North America to gain regulatory approval for new products. This gives North American patients early access to innovative pain relief technologies, fostering market leadership.
Asia-Pacific is growing at the fastest pace in the pain management devices market
Asia-Pacific is increasingly adapting global pain management technologies to local needs, leading to rapid market growth. For instance, the Abbott Proclaim XR system has been adapted for use in countries like India and China with specific features tailored to the local healthcare landscape. This device offers both spinal cord stimulation and peripheral nerve stimulation, making it suitable for a wide range of chronic pain conditions prevalent in the region.
The major market players and emerging players in the region developing advanced smart devices for pain management. For instance, in September 2022, UltrcareCare Pro introduced TENS 2.0, a Smart - Wearable, Wireless and Pocket-sized Pain Management Device for joint, muscular and everyday pain featuring a modern design that is truly wireless with the size of a smartwatch.
Increasing awareness of chronic pain and available treatments is driving market growth in APAC. Government and non-governmental organizations are conducting awareness campaigns about the benefits of pain management devices. For instance, in Australia, initiatives by Pain Australia have highlighted the benefits of devices like spinal cord stimulators and how they can improve the quality of life for chronic pain patients. These programs are educating both healthcare providers and patients, leading to higher adoption rates of pain management devices.
Major Global Players
The major global players in the pain management devices market include Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Stryker Corporation, Nevro Corp, Aleva Neurotherapeutics, Zynex Inc., ICU Medical, Inc., inomed Medizintechnik GmbH, Enovis Corporation and among others.
Market Scope
| Metrics | Details | |
| CAGR | 9.2% | |
| Market Size Available for Years | 2018-2033 | |
| Estimation Forecast Period | 2025-2033 | |
| Revenue Units | Value (US$ Bn) | |
| Volume (Units) | ||
| Segments Covered | Product Type | Neurostimulation Devices, Ablation Devices, Infusion Pumps, Electrical Stimulation Devices |
| Application | Neuropathic Pain, Cancer Pain, Musculoskeletal Pain, Migraine Pain, Others | |
| End-User | Hospitals, Specialty Clinics, Homecare Settings, Physiotherapy Centers, Others | |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa | |
Why Purchase the Report?
- Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
- Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
- Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
- Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
- Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
- Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
- Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
- Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
- Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
- Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
- Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
- Post-market Surveillance: Uses post-market data to enhance product safety and access.
- Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
The global pain management devices market report delivers a detailed analysis with 62 key tables, more than 57 visually impactful figures, and 187 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2025
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.
